SG11202010521VA - Use of neutrophil elastase inhibitors in liver disease - Google Patents
Use of neutrophil elastase inhibitors in liver diseaseInfo
- Publication number
- SG11202010521VA SG11202010521VA SG11202010521VA SG11202010521VA SG11202010521VA SG 11202010521V A SG11202010521V A SG 11202010521VA SG 11202010521V A SG11202010521V A SG 11202010521VA SG 11202010521V A SG11202010521V A SG 11202010521VA SG 11202010521V A SG11202010521V A SG 11202010521VA
- Authority
- SG
- Singapore
- Prior art keywords
- liver disease
- neutrophil elastase
- elastase inhibitors
- inhibitors
- neutrophil
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862662074P | 2018-04-24 | 2018-04-24 | |
| PCT/US2019/028551 WO2019209738A1 (en) | 2018-04-24 | 2019-04-22 | Use of neutrophil elastase inhibitors in liver disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202010521VA true SG11202010521VA (en) | 2020-11-27 |
Family
ID=68236763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202010521VA SG11202010521VA (en) | 2018-04-24 | 2019-04-22 | Use of neutrophil elastase inhibitors in liver disease |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10806735B2 (en) |
| EP (1) | EP3784657A4 (en) |
| JP (1) | JP2021522247A (en) |
| KR (1) | KR20210002573A (en) |
| CN (1) | CN113614070A (en) |
| AU (1) | AU2019257632A1 (en) |
| CA (1) | CA3101274A1 (en) |
| IL (1) | IL278207A (en) |
| SG (1) | SG11202010521VA (en) |
| TW (1) | TW202011965A (en) |
| WO (1) | WO2019209738A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| CN116615416A (en) | 2020-08-25 | 2023-08-18 | 伊莱利利公司 | Polymorphs of SSAO inhibitors |
| CN114085173B (en) * | 2021-10-18 | 2024-04-16 | 嘉兴学院 | Preparation method of 2-nitro-4-methylsulfonyl benzaldehyde |
| CN117357508B (en) * | 2023-11-03 | 2024-05-17 | 中山大学孙逸仙纪念医院 | Application of ciliristat in preparation of medicine for treating primary cholangitis |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY150285A (en) * | 2007-12-20 | 2013-12-31 | Bayer Ip Gmbh | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use |
| US9475779B2 (en) | 2014-07-31 | 2016-10-25 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| MX2017003215A (en) * | 2014-09-12 | 2018-01-24 | Tobira Therapeutics Inc | Cenicriviroc combination therapy for the treatment of fibrosis. |
| WO2016050835A2 (en) | 2014-10-02 | 2016-04-07 | Ruprecht-Karls-Universität Heidelberg | Selective inhibitors of neutrophil elastase for treating neuropathic pain and chronic pain states harbouring a neuropathic component |
| AU2016205138A1 (en) * | 2015-01-09 | 2017-07-13 | Gilead Apollo, Llc | ACC inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease |
| WO2016146607A1 (en) | 2015-03-18 | 2016-09-22 | Bayer Pharma Aktiengesellschaft | Method for producing (4s)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile |
| BR112017021311A2 (en) * | 2015-04-07 | 2018-06-26 | Intercept Pharmaceuticals Inc | pharmaceutical compositions for combination therapy |
| US20190008867A1 (en) | 2015-11-13 | 2019-01-10 | Ph Pharma Co., Ltd. | 4-(4-cyano-2-thioaryl)dihydropyrimidinones for treating chronic wounds |
| GB201608453D0 (en) | 2016-05-13 | 2016-06-29 | Univ Liverpool | Muscle regeneration |
| EP3518918A4 (en) * | 2016-09-28 | 2020-04-22 | Eiger Biopharmaceuticals, Inc. | Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis |
-
2019
- 2019-04-22 SG SG11202010521VA patent/SG11202010521VA/en unknown
- 2019-04-22 US US16/390,970 patent/US10806735B2/en active Active
- 2019-04-22 CA CA3101274A patent/CA3101274A1/en active Pending
- 2019-04-22 CN CN201980040583.1A patent/CN113614070A/en active Pending
- 2019-04-22 JP JP2020559442A patent/JP2021522247A/en active Pending
- 2019-04-22 EP EP19793755.0A patent/EP3784657A4/en active Pending
- 2019-04-22 KR KR1020207033317A patent/KR20210002573A/en unknown
- 2019-04-22 WO PCT/US2019/028551 patent/WO2019209738A1/en unknown
- 2019-04-22 AU AU2019257632A patent/AU2019257632A1/en active Pending
- 2019-04-24 TW TW108114343A patent/TW202011965A/en unknown
-
2020
- 2020-09-21 US US17/027,617 patent/US20210069192A1/en not_active Abandoned
- 2020-10-21 IL IL278207A patent/IL278207A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019257632A1 (en) | 2020-11-26 |
| CA3101274A1 (en) | 2019-10-31 |
| CN113614070A (en) | 2021-11-05 |
| US10806735B2 (en) | 2020-10-20 |
| EP3784657A4 (en) | 2022-02-09 |
| JP2021522247A (en) | 2021-08-30 |
| US20190321364A1 (en) | 2019-10-24 |
| US20210069192A1 (en) | 2021-03-11 |
| EP3784657A1 (en) | 2021-03-03 |
| TW202011965A (en) | 2020-04-01 |
| WO2019209738A1 (en) | 2019-10-31 |
| IL278207A (en) | 2020-11-30 |
| KR20210002573A (en) | 2021-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278207A (en) | Use of neutrophil elastase inhibitors in liver disease | |
| MA45937A (en) | AMINO PYRIMIDINE SSAO INHIBITORS | |
| IL259950B (en) | Pyrimidine derivative compounds for use in treatment of cancer and inflammatory disease | |
| BR112016020199A2 (en) | Human plasma kallikrein inhibitor compound, pharmaceutical composition comprising said compound, kit and its use | |
| MA52413A (en) | CD73 INHIBITORS | |
| ZA201800453B (en) | Tissue factor pathway inhibitor antibodies and uses thereof | |
| MA52004A (en) | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | |
| ZA201802373B (en) | Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof | |
| GB201807014D0 (en) | Factor xlla inhibitors | |
| ZA201607740B (en) | Treatment of the complications of chronic liver disease with caspase inhibitors | |
| IL263089A (en) | Imidazolone compounds as human neutrophil elastase inhibitors | |
| MA49006A (en) | IP6K INHIBITORS | |
| EP3897670A4 (en) | Inhibitors of sarm1 in combination with neuroprotective agents | |
| IL282350A (en) | Rgmc-selective inhibitors and use thereof | |
| EP3149192A4 (en) | Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers | |
| ZA202102192B (en) | Fgfr4 inhibitor and use thereof | |
| IL281357A (en) | Cd73 inhibitors and pharmaceutical uses thereof | |
| EP3549930C0 (en) | Novel ester compound and pin1 inhibitor, inflammatory disease therapeutic, and colon cancer therapeutic in which said ester compound is used | |
| IT201700111939A1 (en) | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF INFLAMMATORY STATES | |
| IT201700060506A1 (en) | Composition for the prevention and / or treatment of diseases associated with inflammation and / or hyperalgesia | |
| ZA201706986B (en) | Compositions for the treatment of kidney and/or liver disease | |
| IL283702A (en) | Markers of disease prognosis in multiple sclerosis | |
| IL290769A (en) | Use of a neutrophil elastase inhibitor in lung disease | |
| GB201911821D0 (en) | Compounds for use in the treatment of liver disease | |
| MA55203A (en) | AZETIDINYL 0-GLYC0PR0TEIN-2-ACETAMID0-2-DESOXY-3-D-GLUC0PYRAN0SIDASE INHIBITORS |